Clinically Meaningful Differences in Patient-Reported Outcomes With Amifostine in Combination With Chemoradiation for Locally Advanced Non-Small-Cell Lung Cancer: An Analysis of RTOG 9801

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 5, 2008, Pages 1378-1384

  Sarna, Linda ^a   Swann, Suzanne ^b   Langer, Corey ^c   Werner Wasik, Maria ^d   Nicolaou, Nicos ^c   Komaki, Ritsuko ^e   Machtay, Mitchell ^d   Byhardt, Roger ^f   Wasserman, Todd ^g   Movsas, Benjamin ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g WASHINGTON UNIVERSITY   (United States)

^h HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Amifostine; Chemoradiation; Esophagitis; Lung cancer; Quality of life

Indexed keywords

AMPLITUDE MODULATION; PATIENT TREATMENT; RADIOTHERAPY;

AMIFOSTINE; CHEMORADIATION; ESOPHAGITIS; LUNG CANCER; QUALITY OF LIFE;

BIOLOGICAL ORGANS;

AMIFOSTINE; CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DYSPHAGIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; SMOKING HABIT; TREATMENT OUTCOME; WEIGHT REDUCTION;

AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DEGLUTITION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PACLITAXEL; QUALITY OF LIFE; RADIATION-PROTECTIVE AGENTS; SEXUAL BEHAVIOR; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 56349137675     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.03.003     Document Type: Article

References (32)

1. Siddiqui F., Kachnic L.A., and Movsas B. Quality-of-life outcomes in oncology. Hematol Oncol Clin North Am 20 (2006) 165-185
2. Fayers P., and Machin D. Quality of life: Assessment, analysis, and interpretation (2000), Wiley, New York
3. Jacox A., Carr D.B., Payne R., et al. Management of cancer pain. Clinical practice guideline no. 9. AHCPR Publication No. 94-0592 (1994), Agency for Health Care Policy and Research, US Department of Health and Human Services, Public Health Service, Rockville, MD
4. Cleeland C.S., Mendoza T.R., Wang X.S., et al. Assessing symptom distress in cancer patients. Cancer 89 (2000) 1634-1646
5. Trotti A., Byhardt R., Stetz J., et al. Common Toxicity Criteria: Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 47 (2000) 13-47
6. Movsas B., Scott C., Langer C., et al. Randomized trial of amifostine in locally advanced non-small cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group Trial 98-01. J Clin Oncol 23 (2005) 2145-2154
7. Aaronson N.K., Ahmedzai S., Berman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
8. Fayers P., Aaronson N.K., Bjordal K., et al. EORTC QLQ-C30 scoring manual. 3rd ed. (2001), EORTC, Brussels, Belgium
9. Bergman B., Aaronson N.K., Ahmedzai S., et al. The EORTC QLQ-LC-13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials-EORTC Study Group on Quality of Life. Eur J Cancer 30A (1994) 635-642
10. Osaba D., Zee B., Pater J., et al. Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian, and lung cancer. Qual Life Res 3 (1994) 353-364
11. Medical Research Council Lung Cancer Working Group. Assessment of quality of life in small-cell lung cancer using a daily diary card developed by the Medical Research Council Lung Cancer Working Party. Br J Cancer 64 (1991) 299-306
12. Osaba D., Rodrigues G., Myles J., et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16 (1998) 139-144
13. Mell L.K., Malik R., Komaki R., et al. Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: A meta-analysis. Int J Radiat Oncol Biol Phys 68 (2007) 111-118
14. Antonadou D., Coliarakis N., Synodinou M., et al. Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys 51 (2001) 915-922
15. Antonadou D., Throuvalas N., Petridis A., et al. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 57 (2003) 402-408
16. Koukourakis M.I., Kyrias G., Kakolyris S., et al. Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study. J Clin Oncol 18 (2000) 2226-2233
17. Komaki R., Lee J.S., Milas L., et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: Report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58 (2004) 1369-1377
18. Leong S.S., Tan E.H., Fong K.W., et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 21 (2003) 1767-1774
19. Senzer N. A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: Preliminary findings. Semin Oncol 29 Suppl. 19 (2002) S38-S41
20. Basch E., Iasonos A., McDonough T., et al. Patient versus clinician symptoms reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. Lancet Oncol 7 (2006) 903-909
21. Jensen K., Jensen A.B., and Grau C. The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnaire. Radiother Oncol 78 (2006) 298-305
22. Sarna L., and Reidinger M.S. Assessment of quality of life and symptom improvement in lung cancer clinical trials. Semin Oncol 31 Suppl. 9 (2004) S1-S10
23. Sloan J., Frost M.H., Berzon R., et al. Clinical Significance Consensus Meeting Group. The clinical significance of quality of life assessments in oncology: A summary for clinicians. Support Care Cancer 14 (2006) 988-998
24. Gridelli C., Gallo C., Di Maio M., et al. A randomised clinical trail of two docetaxel regimens (weeky vs 3 week) in the second-line treatment of non-small cell lung cancer. The DISTAL 01 study. Br J Cancer 91 (2004) 1996-2004
25. Gritz E., Vidrine D.J., and Lazev A.B. Smoking cessation in cancer patients: Never too late to quit. In: Given B., Given C.W., Champion V., et al. (Eds). Evidenced based interventions in oncology (2003), Springer, New York 107-140
26. Cleeland C., Janjan N.A., Scott C.B., et al. Cancer pain management by radiotherapists: A survey of radiation therapy oncology group physicians. Int J Radiat Oncol Biol Phys 47 (2000) 203-208
27. Gritz E.R., Dresler C., and Sarna L. Smoking, the missing drug interaction in clinical trials: Ignoring the obvious. Cancer Epidemiol Biomarkers Prev 14 (2005) 2287-2293
28. Browman G., Wong G., Hodson I., et al. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 328 (1993) 159-163
29. Browman G., Mohide E.A., Willan A., et al. Association between smoking during radiotherapy and prognosis in head and neck cancer: A follow-up study. Head Neck 24 (2002) 1031-1037
30. Konski A.A., Pajak T.F., Movsas B., et al. Disadvantage of men living alone participating in Radiation Therapy Oncology Group head and neck trials. J Clin Oncol 24 (2006) 4177-4183
31. Sprangers M., and Schwartz C. The challenge of response shift for quality-of-life-based clinical oncology research. Ann Oncol 10 (1999) 747-749
32. Broberger E., Sprangers M., and Tishelman C. Do internal standards of quality of life change in lung cancer patients?. Nurs Res 55 (2006) 274-282